DK3426681T3 - Åbne hla-b57-konformere - Google Patents

Åbne hla-b57-konformere Download PDF

Info

Publication number
DK3426681T3
DK3426681T3 DK17709093.3T DK17709093T DK3426681T3 DK 3426681 T3 DK3426681 T3 DK 3426681T3 DK 17709093 T DK17709093 T DK 17709093T DK 3426681 T3 DK3426681 T3 DK 3426681T3
Authority
DK
Denmark
Prior art keywords
conformers
hla
open
open hla
Prior art date
Application number
DK17709093.3T
Other languages
English (en)
Inventor
Belaunzaran Osiris Marroquin
Christoph Renner
Ulf Petrausch
Original Assignee
Univ Zuerich
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich, Univ Basel filed Critical Univ Zuerich
Application granted granted Critical
Publication of DK3426681T3 publication Critical patent/DK3426681T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK17709093.3T 2016-03-08 2017-03-07 Åbne hla-b57-konformere DK3426681T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16159099 2016-03-08
PCT/EP2017/055373 WO2017153438A1 (en) 2016-03-08 2017-03-07 Hla-b57 open conformers

Publications (1)

Publication Number Publication Date
DK3426681T3 true DK3426681T3 (da) 2020-11-16

Family

ID=55586142

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17709093.3T DK3426681T3 (da) 2016-03-08 2017-03-07 Åbne hla-b57-konformere

Country Status (13)

Country Link
US (2) US11369660B2 (da)
EP (2) EP3426681B1 (da)
JP (1) JP6980196B2 (da)
KR (1) KR102456666B1 (da)
CN (1) CN108779164B (da)
AU (2) AU2017230855B2 (da)
BR (1) BR112018068135A2 (da)
CA (1) CA3016752C (da)
DK (1) DK3426681T3 (da)
ES (2) ES3009108T3 (da)
MX (1) MX392624B (da)
WO (1) WO2017153438A1 (da)
ZA (1) ZA201805743B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112024002196A2 (pt) 2021-08-05 2024-04-30 Immunos Therapeutics Ag Hla-b57 modificado com níveis de expressão aumentados
IL310617A (en) 2021-08-05 2024-04-01 Immunos Therapeutics Ag Combination drugs that include HLA FUSION proteins
EP4129323A1 (en) 2021-08-05 2023-02-08 ImmunOs Therapeutics AG A modified hla-b57 with increased expression levels
EP4130029A1 (en) 2021-08-05 2023-02-08 ImmunOs Therapeutics AG Pharmaceutical compositions comprising hla fusion proteins
AU2024217729A1 (en) 2023-02-08 2025-08-21 Immunos Therapeutics Ag FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810099D0 (en) 1998-05-11 1998-07-08 Isis Innovation Novel molecule and diagnostic method
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
ATE346278T1 (de) 2000-03-30 2006-12-15 Topcon Corp Stereobildmessvorrichtung
WO2003018745A2 (en) * 2001-08-21 2003-03-06 Glaxo Group Limited Method of screening for drug hypersensitivity reaction
EP2292638A3 (en) 2002-09-27 2011-03-23 Ludwig Institute For Cancer Research MAGE-C2 antigenic peptides and uses thereof
WO2005005631A1 (ja) 2003-07-11 2005-01-20 Dainippon Sumitomo Pharma Co., Ltd. リビン由来のhla-a24結合性癌抗原ペプチド
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
WO2007011044A1 (ja) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法
US7842466B1 (en) 2005-09-16 2010-11-30 Celera Corporation Colon disease targets and uses thereof
US8168586B1 (en) 2007-11-21 2012-05-01 Celera Corporation Cancer targets and uses thereof
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗-hla-b*27抗體及其用途
CN103184291A (zh) * 2013-04-07 2013-07-03 上海血液生物医药有限责任公司 一种检测人hla-b*57:01等位基因的试剂盒
US20160186265A1 (en) 2013-08-15 2016-06-30 Centre Hospitalier Universitarie Vaudois Methods for Typing HLA Alleles
US10816554B2 (en) * 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
CA2973641A1 (en) 2015-02-04 2016-08-11 Universitat Zurich Use of hla-b27 homodimers for cancer treatment

Also Published As

Publication number Publication date
JP2019512231A (ja) 2019-05-16
ZA201805743B (en) 2022-03-30
CA3016752A1 (en) 2017-09-14
EP3795588A2 (en) 2021-03-24
EP3426681B1 (en) 2020-08-26
KR102456666B1 (ko) 2022-10-19
KR20180119605A (ko) 2018-11-02
EP3795588C0 (en) 2024-12-18
WO2017153438A1 (en) 2017-09-14
CA3016752C (en) 2024-09-17
US11369660B2 (en) 2022-06-28
AU2021202634A1 (en) 2021-05-27
US12383602B2 (en) 2025-08-12
AU2017230855A1 (en) 2018-09-27
AU2017230855B2 (en) 2021-05-27
CN108779164B (zh) 2023-06-09
EP3795588B1 (en) 2024-12-18
MX392624B (es) 2025-03-24
MX2018010836A (es) 2019-03-28
JP6980196B2 (ja) 2021-12-15
BR112018068135A2 (pt) 2019-01-08
ES3009108T3 (en) 2025-03-26
EP3426681A1 (en) 2019-01-16
US20190247466A1 (en) 2019-08-15
AU2021202634B2 (en) 2022-09-15
ES2828086T3 (es) 2021-05-25
CN108779164A (zh) 2018-11-09
US20220339250A1 (en) 2022-10-27
EP3795588A3 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
DK3405050T3 (da) Børnesikret snusbeholder
EP3417133C0 (en) HINGE
EP3446605A4 (en) HAND VACUUM
DK3436823T3 (da) Antigen-array
EP3455498A4 (en) Fuel delivery injector
EP3445380C0 (en) BACTERIOTHERAPY
EP3450133A4 (en) Liquid blow molding method
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
EP3465295A4 (en) STACK OF POLARIZERS
DK3445708T3 (da) Stigbøjle
EP3484035A4 (en) HYSTERESIS SUPPLY CIRCUIT
EP3402021A4 (en) GRAB WIRE
DK3452590T3 (da) Plademagnet
EP3478921A4 (en) PULL CORD ARRANGEMENT
EP3475155A4 (en) WING SAILING BOAT
DOS2016000090S (es) Cierre
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
DK3575238T3 (da) Pallecontainer
EP3471668C0 (en) CORK
EP3399976C0 (en) BENZOTHIAZOLE AMPHOPHILES
ZA201805743B (en) Hla-b57 open conformers
EP3473285A4 (en) Injector
DE112017000734A5 (de) Glycolsensor
DE112017006386A5 (de) Schraubarbeitszylinder